IQVIA (IQV) Projected to Post Earnings on Tuesday

IQVIA (NYSE:IQV) is anticipated to post its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect IQVIA to post earnings of $2.96 per share and revenue of $4.0738 billion for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 9:00 AM ET.

IQVIA Price Performance

NYSE IQV opened at $220.64 on Friday. IQVIA has a 12 month low of $134.65 and a 12 month high of $225.91. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $37.51 billion, a PE ratio of 31.93, a P/E/G ratio of 2.42 and a beta of 1.32. The company’s 50 day simple moving average is $194.47 and its 200 day simple moving average is $171.46.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Barclays lifted their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Evercore ISI lifted their price target on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $235.00 in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $234.57.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Worldquant Millennium Advisors LLC lifted its stake in shares of IQVIA by 90.8% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 429,802 shares of the medical research company’s stock valued at $67,732,000 after purchasing an additional 204,571 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in IQVIA by 10.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 339,817 shares of the medical research company’s stock worth $53,552,000 after acquiring an additional 32,161 shares during the period. Man Group plc raised its holdings in IQVIA by 23.3% in the 2nd quarter. Man Group plc now owns 202,428 shares of the medical research company’s stock worth $31,901,000 after acquiring an additional 38,229 shares during the period. Finally, MML Investors Services LLC raised its holdings in IQVIA by 32.0% in the 2nd quarter. MML Investors Services LLC now owns 180,834 shares of the medical research company’s stock worth $28,498,000 after acquiring an additional 43,821 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.